Semax Reference
Educational, not medical advice reference for Semax: Cognitive; regulatory status, evidence posture, source review, and schedule notes. Also kno…
Plain English
- What it is
- Semax is a lab-made peptide built from a small piece of a natural brain hormone called ACTH. It was developed in Russia and is usually given as a nasal spray. It is not approved by the FDA in the United States and is treated as a research chemical here.
- What people use it for
- In the community, people use Semax hoping for sharper focus, more mental energy, and help clearing brain fog or bouncing back after a stroke. Users often describe the effect as subtle rather than stimulant-like, and this kind of self-reported use is anecdotal, not proof it works.
- What the science shows
- Most published, peer-reviewed studies are in animals, mainly rats, covering stroke-related brain injury and brain growth-signal genes. In Russia it has been used in the clinic for ischemic stroke, but English-language human evidence stays limited and is not well repeated in the West.
- The catch
- Because it is not FDA approved, its US legal status is unsettled, and an FDA advisory committee is set to discuss in July 2026 whether it may even be compounded. Most evidence is still animal research, so it is best viewed as experimental rather than a proven medicine, and as a research-grade product, measuring mistakes are easy to make.
Reference summary
Most accessible peer-reviewed evidence is preclinical, largely in rodent ischemia and neurotrophin-expression models. English-language human evidence remains limited despite reports of Russian clinical use.
Regulatory and posture
- Categories
- Cognitive
- Aliases
- Semax heptapeptide, ACTH(4-7) Pro-Gly-Pro analog
- Evidence posture
- translational - Accessible evidence is mostly preclinical or older non-US literature.
- Regulatory status
- No FDA-approved Semax drug label. Semax is registered in Russia for neurological indications and sits in FDA's table of bulk drug substances previously in Category 2 whose nominations were withdrawn. It is not on the 503A Bulks List and is not permitted for 503A pharmacy compounding. At the July 24, 2026 Pharmacy Compounding Advisory Committee meeting the committee narrowly recommended it for inclusion, against FDA's own reviewers; that recommendation does not bind FDA and changes nothing unless and until FDA completes rulemaking.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: Semax rat ischemia study
- PubMed: Semax neurotrophin rat study
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
For research and educational purposes only. Not medical advice.